• Co-Targeting BRD4 and RAC1 Disrupts c-MYC Axis in Breast Can

  2026-04-29

  This study demonstrates that dual inhibition of BET bromodomain BRD4 and RAC1 suppresses growth, stemness, and tumorigenesis across breast cancer subtypes by disrupting the c-MYC/G9a/FTH1 pathway and downregulating HDAC1. The findings highlight the therapeutic promise of modulating chromatin remodeling and epigenetic regulators in oncology.

• Pioglitazone: Applied PPARγ Agonist Strategies in IBD & Meta

  2026-04-29

  Pioglitazone (SKU B2117), a selective PPARγ agonist from APExBIO, empowers researchers to dissect macrophage polarization, insulin resistance, and inflammatory modulation with unmatched workflow clarity. This guide translates the latest reference breakthroughs and hands-on troubleshooting into practical protocols for metabolic disorder and neuroinflammation research.

• Z-VAD-FMK in Apoptosis Inhibition: Advanced Use Cases & Prot

  2026-04-28

  Z-VAD-FMK (Benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone) from APExBIO empowers researchers to dissect apoptosis with precision, optimizing caspase inhibition in diverse cellular models. This guide details applied workflows, troubleshooting, and data-driven tips to maximize reliability in apoptosis and immune signaling studies.

• Trelagliptin Succinate: Rethinking Diabetes Research Frontie

  2026-04-28

  This thought-leadership article explores the mechanistic and translational value of Trelagliptin succinate (SYR-472 succinate) for type 2 diabetes treatment and related complications. Integrating the latest evidence—including novel findings on cognitive impairment and inflammation—this piece delivers actionable protocol guidance, critically appraises the competitive landscape, and outlines strategic outlooks for translational researchers. Building on foundational resources, it charts new territory by bridging metabolic, inflammatory, and neurocognitive research domains.

• PTX3-TLR4/NF-κB-FGF21 Axis in Glucocorticoid-Induced ONFH

  2026-04-27

  Li et al. elucidate how pentraxin 3 (PTX3) protects against glucocorticoid-induced osteonecrosis of the femoral head (ONFH) by modulating the TLR4/NF-κB/FGF21 signaling axis. This mechanistic insight reveals new intervention points for bone metabolism research and highlights the relevance of PKC/NF-κB pathway inhibitors in dissecting osteogenic regulation.

• Risedronate Sodium: FPPS Inhibitor Workflow for Bone Researc

  2026-04-27

  Risedronate Sodium, a potent FPP synthase inhibitor, advances bone metabolism research through diverse delivery systems and robust anti-resorptive efficacy. Explore optimized experimental workflows, comparative innovations, and troubleshooting grounded in recent nanopatch delivery breakthroughs.

• NF 340: Transforming P2Y11 Antagonist Use in Cancer Research

  2026-04-26

  NF 340, a highly selective P2Y11 antagonist, empowers researchers to dissect GPCR signaling with unmatched specificity—especially in cancer invasiveness and immunology workflows. This guide details hands-on protocol strategies, troubleshooting insights, and the translational leap enabled by NF 340, referencing breakthrough findings in breast cancer cell migration.

• Advancing In Vitro Drug Response Evaluation in Cancer Resear

  2026-04-25

  Schwartz's dissertation introduces a refined framework for distinguishing between proliferative arrest and cell death in anti-cancer drug testing. By clarifying the interpretation of in vitro assay metrics, the study informs more accurate preclinical evaluation and translational decision-making.

• RBMS1 Loss Enhances Anti-Tumor Immunity in Triple-Negative B

  2026-04-24

  This study identifies the RNA-binding protein RBMS1 as a key regulator of PD-L1 stability in triple-negative breast cancer (TNBC). Its loss enhances anti-tumor immunity by promoting PD-L1 degradation, offering a novel immunotherapeutic target for improving checkpoint blockade efficacy.

• H-89: Applied cAMP-Dependent Protein Kinase Inhibitor Workfl

  2026-04-24

  H-89 delivers precise, selective inhibition of protein kinase A—empowering researchers to dissect cAMP signaling in bone, metabolic, and apoptosis assays. See how recent breakthroughs in metabolic bone research translate into optimized experimental design and troubleshooting for robust, reproducible results.

• Rotigotine’s Dual Impact: Dopaminergic Modulation and Bladde

  2026-04-23

  Explore how Rotigotine, a potent dopamine D2/D3 receptor agonist, uniquely advances Parkinson’s disease research by elucidating both motor and non-motor symptom pathways. This article delivers a deep dive into novel neuro-urological insights, mechanistic findings, and advanced assay strategies unavailable in standard guides.

• Fluorouracil (Adrucil) in Solid Tumor Research: Optimized Wo

  2026-04-23

  Fluorouracil (Adrucil) empowers precise inhibition of DNA replication in colon and breast cancer research, backed by reproducible cytotoxicity benchmarks and advanced protocol guidance. This article delivers actionable workflows, troubleshooting insights, and the latest translational applications—anchored by peer-reviewed evidence and APExBIO’s trusted supply.

• Mitoxantrone HCl: DNA Topoisomerase II Inhibitor Workflows

  2026-04-22

  Mitoxantrone HCl stands out as a dual-action DNA topoisomerase II inhibitor for both cytotoxicity and nuclear receptor modulation, enabling advanced research in cancer biology and beyond. This article delivers actionable workflows, troubleshooting guidance, and a synthesis of recent breakthroughs for maximizing assay performance with this APExBIO reagent.

• Propranolol: Mechanistic Insights and Strategic Impact in Tr

  2026-04-22

  This article presents a thought-leadership perspective on Propranolol, a non-selective β-adrenergic receptor blocker, focusing on its mechanistic actions, translational significance, and experimental best practices for researchers. Integrating recent meta-analytic evidence, competitive intelligence, and workflow guidance, we highlight how Propranolol (SKU: BA1217) from APExBIO enables innovative research avenues in cardiovascular, neuropsychiatric, and metabolic domains.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-04-21

  Schwartz's dissertation introduces a critical distinction between relative viability and fractional viability in in vitro cancer drug testing, enabling more precise interpretation of anti-cancer compound effects. This approach clarifies the interplay between proliferation arrest and apoptosis, improving the reliability of preclinical drug evaluation.

15096 records 1/1007 page Next 12345 下5页 Last page